Myeloperoxidase up-regulation during haemodialysis: is heparin the missing link?
نویسندگان
چکیده
Myeloperoxidase up-regulation during haemodialysis: is heparin the missing link? Sir, We read with interest the recent series of articles showing a striking increase in blood myeloperoxidase (MPO) levels during haemodialysis (HD) sessions [1–3]. In this setting, the enzyme is traditionally regarded as a marker of neutrophil degranulation and thus, of dialyser membrane biocompat-ibility, as well as generation of oxidative stress [1–5]. Some results of the above studies and their interpretations seem, however, not to be corroborated enough and indicate the existence of other unrecognized factors responsible for MPO up-regulation during HD [1,2]. For example, in the study by Wu et al. [1] the increase in plasma MPO was as much as 3-fold vs baseline with a biocompatible polysulfone membrane, occurring as early as 15 min from the start of HD and, surprisingly, was not accompanied by a fall in circulating neutrophil counts. In the study by Gritters et al. [2] serum MPO levels almost doubled after the first passage of blood through the high-flux polysulfone dialyser. Notably, the effect was only observed when either unfractionated heparin or low-molecular-weight heparin dalteparin was used for temporary HD anticoagulation, and then disappeared with regional trisodium citrate anticoagulation [2]. The authors ascribed the latter absence of MPO release to the calcium-free environment created within the dialyser, and suggested that it could be a valuable approach to avoid overdialytic neutrophil degranulation. They seem, however, to have overlooked the previous report indicating no MPO up-regulation during HD treatments anticoagulated with nafamostate mesylate instead of heparin [4]. In the most recent trial, Krieter et al. [3] showed a remarkable, 6-fold rise in blood MPO levels taking place 5 min after the start of HD. They also revealed a small ($9%) but significant difference between MPO levels in blood leaving vs entering the filter, which confirms the actual but negligible intra-dialyser neutrophil degranulation. On the basis of the early high MPO levels in the pre-dialyser blood, the authors attentively concluded that the contact of blood with the filter membrane could not be the only cause of MPO generation [3]. Unfortunately, both Wu et al. [1,5] and Krieter et al. [3] failed to specify the anticoagulation strategy used in their HD patients, ascribed the very early MPO upregulation to either 'the dialysis per se and dialysate contaminants' [5] or 'shear forces through the blood pump' [3] and prematurely ended with the statement that MPO is a useful and reliable …
منابع مشابه
Sonoclot coagulation analysis: new bedside monitoring for determination of the appropriate heparin dose during haemodialysis.
BACKGROUND Thrombotic and haemorrhagic complications affect cardiovascular morbidity and mortality in haemodialysis patients. We investigated whether a new bedside Sonoclot analysis is useful for determining an appropriate heparin dose during haemodialysis. METHODS Twenty-two haemodialysis patients (15 males and seven females) treated with unfractionated heparin were recruited. Sonoclot param...
متن کاملMonitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
In haemodialysis low-molecular-weight (LMW) heparin is increasingly used for anticoagulation. The advantages over unfractionated (UF) heparin are the lower bleeding risk and the lack of influence on lipid metabolism. However, no reliable and rapid method is available so far to control the efficacy and safety of LMW heparin during haemodialysis. The specific anti-factor Xa (aXa) chromogenic subs...
متن کاملPharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.
BACKGROUND The interest of low molecular weight heparins (LMWH) regarding bleeding risk is controversial in renal failure patients. In haemodialysis patients, there are very few data on the pharmacokinetics of LMWH after the end of the session. The aim of the study was to evaluate the duration of anticoagulation after bolus administration of the LMWH enoxaparin at the start of haemodialysis. ...
متن کاملThe effect of citrate dialysate on intradialytic heparin dose in haemodialysis patients: study design of a randomised controlled trial
BACKGROUND Unfractionated heparin is the most common anticoagulant used in haemodialysis (HD), although it has many potential adverse effects. Citrate dialysate (CD) has an anticoagulant effect which may allow reduction in cumulative heparin dose (CHD) compared to standard acetate dialysate (AD). METHODS This double-blinded, randomised, cross-over trial of chronic haemodialysis patients deter...
متن کاملDoes tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?
Link and colleagues present a pilot study investigating platelet function and platelet numbers in patients with cardiogenic shock and acute kidney failure undergoing continuous venovenous haemodialysis. Their data indicate a significantly reduced platelet loss with combined therapy of unfractionated heparin plus tirofiban, the glycoprotein IIb/IIIa antagonist, compared with unfractionated hepar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
دوره 21 4 شماره
صفحات -
تاریخ انتشار 2006